4:59 is 5AM’s hands-on internal effort to discover, incubate, and fund breakthrough science. We seek to partner alongside academics and entrepreneurs – often serving as an extension of the operating team – to establish proof-of-concept data that will enable a Series A Financing.
5AM Ventures Strategy primarily invests in private therapeutic companies. The funds are typically early-stage focused, with an emphasis on Series A companies.
5AM Opportunities Strategy invests in small and mid-cap public and later-stage private biotech and life science companies.
We’re a life science venture capital firm founded in 2002 and currently investing $450M from 5AM Ventures VII and $300M from 5AM Opportunities II.
Our focus is biopharmaceuticals, drug delivery technologies and life science instruments.
Historically our portfolio companies have had over 80,000 patients enrolled across 8,000 test sites in clinical trials.